Survival benefit reported in CheckMate -9LA Study of nivolumab plus ipilimumab with limited chemotherapy vs. chemotherapy alone as first-line treatment of metastatic non-small cell lung cancer

At a prespecified interim analysis for the primary endpoint of overall survival, nivolumab plus ipilimumab combined with 2 cycles of chemotherapy reduced risk of death by 31% vs. chemotherapy alone at a minimum follow-up of 8.1 months (HR 0.69, 96.71% CI, 0.55 to 0.87; p=0.0006).


Biospace Inc.